W
NKTR icon

WealthCollab’s Nektar Therapeutics NKTR Stock Holding History

WealthCollab’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20
Closed -$372 – 917
2024
Q2 		$372 Hold
20
– – ﹤0.01% 838
2024
Q1 		$281 Hold
20
– – ﹤0.01% 841
2023
Q4 		$170 Buy
+20
New +$151 ﹤0.01% 873

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WealthCollab's NKTR Position: Q3 2024 in Review

WealthCollab sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 20 shares — an estimated $372 sold.

WealthCollab first reported a position in NKTR in Q4 2023 and held it in 3 quarters. The position peaked at $372 in Q2 2024. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • WealthCollab reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • WealthCollab sold 20 Nektar Therapeutics shares in Q3 2024, an estimated $372.
  • WealthCollab first reported a position in Nektar Therapeutics in Q4 2023 and held it in 3 quarters.
  • WealthCollab's Nektar Therapeutics position peaked at $372 in Q2 2024.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on WealthCollab's 13F filing for Q3 2024, filed 14 Nov 2024.